ep262
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 30, 2023 (NCT06050928)
Timeline
Indications
Mechanism of action
MRGPRX2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06645704 | Phase 1 | Oct 31, 2024 | Escient Pharmaceuticals, Inc |
| NCT06144424 | Phase 2 | Nov 30, 2023 | Escient Pharmaceuticals, Inc |
| NCT06077773 | Phase 2 | Sep 25, 2023 | Escient Pharmaceuticals, Inc |
| NCT06050928 | Phase 1 | Aug 30, 2023 | Escient Pharmaceuticals, Inc |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Escient Pharmaceuticals, Inc | For profit | 4 | 4 | 2 | 2023 |
1 organizations
Page 1 / 1